Advertisement

Topics

Search Results for "CT P6 Celltrion"

11:34 EDT 29th April 2017 | BioPortfolio

Matching Channels

None

Matching News

Celltrion Healthcare IPO Set To Benefit From Biosimilar Successes

Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare...   

BRIEF-Celltrion signs 149.10 bln won contract with Celltrion Healthcare

* Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima

Celltrion seeks to introduce more biosimilars in US

More biosimilars from a South Korean drugmaker could join Celltrion's Remicade biosimilar Inflectra, or Remsima, in the US ma -More- 

BRIEF-Celltrion signs contract worth 53.25 bln won

* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug

Celltrion receives EU approval for Rituxan biosimilar

The European Medicines Agency has approved Celltrion's Truxima, a biosimilar for Roche Holding's leukemia treatment Rituxan/M -More- 

Celltrion's MabThera cleared by EC for autoimmune diseases and cancer

The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.

Teva: ‘Celltrion deal will double biosimilar sales to $600m’

Celltrion deal and multi-million Euro German plant will make it a major second and third wave biosimilars player says Teva.

Celltrion sets sights on 2017 for EU and US rituximab biosimilar success

Celltrion is confident that 2017 will bring European approval and a US filing for Truxima, after achieving regulatory success for the Rituxan biosimilar in Korea.

Matching PubMed Articles

None

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement